GET DAILY SIGNALSTransMedics Group (TMDX) Delivers Record Revenue with +41% YoY Growth in Q3 2026
Key Takeaways
- TransMedics Group reported third quarter 2026 revenue of $203 million, up 41% year over year and its highest quarterly revenue on record, topping analyst expectations.
- Non-GAAP (adjusted) earnings per share (EPS) came in at $0.51, well above the consensus estimate, while GAAP diluted EPS was $0.46.
- Management raised full-year 2026 revenue guidance to $764 million–$774 million, implying roughly 26%–28% growth over 2025.
- Gross margin dipped to 58.5% as lower-margin service revenue and the newly acquired PAD Aviation business grew faster than product sales.
- Investors can find more on the company's Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
- Explore Trending AI Robots to see how AI-driven trading tools are identifying market opportunities.
Why the Quarter Matters
TransMedics Group, a medical technology company known for its Organ Care System (OCS) and National OCS Program (NOP), has become a closely watched growth story in the transplant market. The company's third quarter 2026 results matter because they show whether its high-growth model can sustain momentum while it simultaneously pours money into clinical trials, a next-generation OCS platform, and international expansion. Coming into the report, TransMedics had already delivered several consecutive quarters of strong revenue gains, but investors were increasingly focused on rising operating expenses and a shifting revenue mix. The quarter offered a direct test of whether top-line momentum could coexist with heavier strategic investment, making it a key checkpoint for both growth and margin expectations. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Results
TransMedics reported third quarter 2026 revenue of approximately $203 million, up 41% year over year and the strongest quarter in company history. Organic revenue, which excludes the contribution from its PAD Aviation acquisition, grew 35% to about $194 million. Product revenue rose 29% to roughly $113 million, while service revenue jumped 60% to about $90 million. U.S. transplant revenue climbed 34% to approximately $186 million, led by liver cases, and international revenue surged 82% to about $6.6 million.
On the bottom line, non-GAAP (adjusted) EPS reached $0.51, beating consensus estimates, while GAAP diluted EPS was $0.46, down from $0.66 a year earlier. Gross margin came in at 58.5%, down about 40 basis points year over year, as lower-margin service revenue grew to 44% of total sales. Excluding PAD Aviation, gross margin was 61.1%. Management raised full-year 2026 revenue guidance to a range of $764 million to $774 million, including roughly $14 million from PAD Aviation. From what I see, the numbers confirm the top-line strength while highlighting the margin trade-offs from the evolving mix.
Market Reaction and Investor Sentiment
Shares of TMDX moved higher in after-hours trading following the release, as the revenue beat and raised full-year guidance outweighed concerns about the quarter's margin mix. The rally offered a measure of relief after a difficult stretch for the stock, which had fallen sharply through 2026 alongside broader investor unease about rising research and development (R&D) spending, clinical trial costs, and the integration of PAD Aviation. Sentiment remained split: bulls pointed to record revenue and accelerating service growth, while more cautious investors focused on the growing share of lower-margin service revenue and the dilution of gross margin from the new aviation business. The raised guidance signaled management's confidence that strong demand would persist into year-end.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will be watching whether TransMedics can convert its record top-line growth into sustained profitability as it continues investing for the next phase of expansion. The company is ramping up spending on its OCS Kidney program, the next-generation OCS platform, and its ENHANCE heart and De Novo lung clinical trials, all of which are expected to weigh on near-term margins even as they build a foundation for future growth.
International expansion is another key theme. Management is building out its NOP model in Europe, beginning with a program in Italy, and continues to integrate PAD Aviation into its logistics network. The mix of product versus service revenue will remain an important margin driver to monitor, since service revenue carries lower margins than product sales. I’m watching this closely as the company scales.
Finally, investors should track the company's progress toward its updated full-year 2026 revenue target of $764 million to $774 million, any updates on clinical trial enrollment, and how efficiently management scales its aircraft fleet and logistics operations. These factors will help determine whether TransMedics can maintain its growth trajectory while gradually expanding profitability.
AI Tools in My Research Process
In my analysis of names like TMDX, I often rely on Tickeron’s AI-powered tools to cross-check patterns and compare performance across the medical technology sector. One platform I turn to regularly is the AI Screener, which lets me filter stocks by fundamentals, technical signals, and industry trends in a matter of minutes. It has become a practical part of my workflow for spotting relative strength and monitoring momentum without spending hours on manual reviews.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for TMDX turns positive, indicating new upward trend
TMDX saw its Momentum Indicator move above the 0 level on November 04, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In 77 of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TMDX's RSI Oscillator exited the oversold zone, 27 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 53 cases where TMDX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for TMDX just turned positive on November 04, 2026. Looking at past instances where TMDX's MACD turned positive, the stock continued to rise in 41 of 48 cases over the following month. The odds of a continued upward trend are 85%.
Following a +9.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMDX advanced for three days, in 254 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
TMDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day moving average for TMDX crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for TMDX entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 28 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.617) is normal, around the industry mean (4.338). P/E Ratio (15.501) is within average values for comparable stocks, (1.324). Projected Growth (PEG Ratio) (0.709) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (5.033) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. TMDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 76 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of a proprietary system for preserving human organs for transplant
Industry MedicalNursingServices
Advertisement